Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY20 results · Jan–Mar 2020
Lincoln Pharmaceuticals reported revenue from operations of ₹75.26 crore (down 2.8% from Q4 FY19) and net profit of ₹9.23 crore (up 28.7% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 75.26 | 77.46 | −2.8% | 95.64 | −21.3% |
| Other income | 5.31 | (0.59) | Turned profit | 2.37 | +124.4% |
| Total income | 80.57 | 76.87 | +4.8% | 98.01 | −17.8% |
| Profit before tax | 11.38 | 6.96 | +63.5% | 12.05 | −5.5% |
| Net profit for the period | 9.23 | 7.17 | +28.7% | 10.18 | −9.3% |
| EPS, basic (₹) | 4.62 | 3.59 | +28.7% | 5.09 | −9.2% |
| Net margin (%) | 12.3 | 9.3 | 10.6 |
Standalone
- Filed with BSE
- 25 Jun 2020, 17:24 IST
- Board meeting
- 25 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE